PepGen (NASDAQ:PEPG) Now Covered by Analysts at Oppenheimer

Research analysts at Oppenheimer initiated coverage on shares of PepGen (NASDAQ:PEPG) in a research note issued to investors on Wednesday,Benzinga reports. The firm set an “outperform” rating and a $15.00 price target on the stock. Oppenheimer’s price target points to a potential upside of 131.48% from the company’s current price.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Guggenheim upped their price target on shares of PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. HC Wainwright lifted their price objective on PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, PepGen has an average rating of “Moderate Buy” and an average target price of $12.60.

PepGen Stock Up 2.5%

Shares of PEPG traded up $0.16 during trading hours on Wednesday, reaching $6.48. The company’s stock had a trading volume of 271,204 shares, compared to its average volume of 701,744. The company has a 50 day moving average of $5.80 and a two-hundred day moving average of $4.50. The firm has a market cap of $445.50 million, a price-to-earnings ratio of -2.30 and a beta of 1.91. PepGen has a 1-year low of $0.88 and a 1-year high of $7.80.

Institutional Trading of PepGen

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its holdings in PepGen by 94.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock worth $73,000 after purchasing an additional 5,453 shares during the last quarter. Heights Capital Management Inc. acquired a new stake in shares of PepGen in the third quarter worth $46,000. Burkehill Global Management LP acquired a new stake in shares of PepGen in the third quarter worth $46,000. Jefferies Financial Group Inc. bought a new stake in shares of PepGen during the 4th quarter worth $89,000. Finally, Militia Capital Partners LP acquired a new position in PepGen in the 3rd quarter valued at $72,000. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).